This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Diabetic Macular Edema
and you are
over 18
years old
Phase
-
The phase for this study is not defined.
Show me locations

The purpose

This trial seeks to prove that sub-lethal laser power levels are as effective and less damaging than traditional laser. Diabetic macular edema (DME) affects approximately 29% of diabetic patients with a disease duration of 20 or more years and is one of the most frequent causes of vision loss in this population. The Early Treatment Diabetic Retinopathy Study (ETDRS) demonstrated a significant benefit of laser photocoagulation for the treatment of clinically significant macular edema, reducing the incidence of vision loss by approximately 50% at 3 years' follow-up.

Provided treatments

  • Procedure: Topcon Endpoint Management laser
Tris trial is registered with FDA with number: NCT01732614. The sponsor of the trial is Retinal Consultants of Arizona and it is looking for 10 volunteers for the current phase.
Official trial title:
Safety Assessment and Therapeutic Effect of Non-damaging Patterned Scanning Laser Phototherapy in Patients With Diffuse Diabetic Macular Edema